Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 11Lung Neoplasms 5Thymus Neoplasms 1Thymoma 1Small Cell Lung Cancer Extensive Stage 1Neoplasms 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1

Interventions

pembrolizumab 3Quality of Life 2Proton Therapy 2Immunotherapy 2Drug Therapy 2fludarabine 1epacadostat 1bosutinib 1amrubicin 1alovudine 1Tumor Burden 1Sunitinib 1Radiotherapy 1Radiosurgery 1Radiation 1Plicamycin 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Histocompatibility Testing 1Erlotinib Hydrochloride 1Cyclophosphamide 1Blood Specimen Collection 1Biological Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thymus Neoplasms × amrubicin × Thoracic × Clear all
NCT01364727 2019-04-16

A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies

Stanford University

Phase 2 Completed
33 enrolled 11 charts
Thoracic

Thymoma, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡